Related Experiment Video
Updated: Apr 27, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
29.3K
Advances in treating glioblastoma
Shiao-Pei Weathers1, Mark R Gilbert1
1Department of Neuro-Oncology, University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd., Unit 431, Houston, TX 77030 USA.
F1000Prime Reports
|July 4, 2014
Summary
Glioblastoma, a common brain cancer, requires new treatments as current therapies offer limited survival benefits. Research into genomic targets, antiangiogenic drugs, and immunotherapy is advancing novel therapeutic strategies.
Area of Science:
- Neuro-oncology
- Cancer Genomics
- Translational Medicine
Background:
- Glioblastoma is the most aggressive primary adult brain tumor.
- Current standard treatments provide only modest improvements in patient survival and disease progression.
- The molecular heterogeneity of glioblastoma necessitates the exploration of novel therapeutic targets and strategies.
Purpose of the Study:
- To highlight the urgent need for novel therapies in glioblastoma treatment.
- To discuss the insights gained from large-scale genomic analyses for identifying actionable targets.
- To review the evolving role of antiangiogenic therapies and the rising potential of immunotherapy.
Main Methods:
- Genomic analyses to understand glioblastoma's molecular landscape.
- Review of current and emerging therapeutic approaches, including antiangiogenic agents and immunotherapy.
- Investigation into optimizing existing treatments and developing new ones.
Main Results:
- Genomic studies have identified potential actionable targets in glioblastoma.
- Antiangiogenic therapies are established but require further optimization.
- Immunotherapy is emerging as a promising therapeutic avenue for gliomas.
Conclusions:
- Novel therapeutic approaches are crucial for improving glioblastoma outcomes.
- Targeted therapies based on genomic insights hold significant promise.
- Continued research and development in immunotherapy offer new hope for glioblastoma patients.
